Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-853-6
CAS number: 100-44-7
During a few minutes after dermal painting of mice a marked irritation
of the eyes, the skin and the respiratory system and a decrease in motor
activities was observed.
the painted area first erythema and swelling were noted later alopecia,
induration, marked keratinization and in some mice ulcers and/or
necrosis of the epidermis were observed.
Total dose: 979 mg/animal
tumor was found in benzene–treated controls or test animals
Total dose: 258 mg/animal
Mortality at termination was 20% in the controls compared and 50% in the
mice of the test group developed squamous–cell carcinomas of the skin
(of which 2 in metastasis), 1 had a leiomyosarcoma of the uterus; 2
treated and 2 control mice had lung adenomas. The difference in skin
cancer incidence was not statistically significant between the two group
authors tested the repeated dose toxicity of benzyl chloride (CAS n°
100-44-7) by painting the clipped back of ICR female mice using two
different sub-chronic experiments. In experiment II mice received 10
μl/animal/painting, three times a week during 4 weeks, and then twice a
week for 37 weeks. In the second experiment (III), mice received 2.3
μl/animal/painting twice a week during 50 weeks. The dose in experiment
II corresponded to approximately 979 mg applied during the entire
exposure period and the dose applied in experiment III was approximately
258 mg. Immediate reactions, mortality and pathological signs were
monitored and tumors were diagnosed and counted in all animals at their
death or at the end of the exposure period.
a few minutes after dermal painting of the treated mice a marked
irritation of the eyes, the skin and the respiratory system as well as
decreased motor activities were seen. Furthermore, at the painted area
first erythema and swelling were noted later alopecia, induration,
marked keratinization and in some mice ulcers and/or necrosis of the
epidermis. More specifically, in experiment II no mortality was
observed, and the treated as well as the control mice were free of
tumors. In the experiment III mortality at termination was 20% for the
control and 50% in the treated group. The number of mice with tumors in
the treated group was 5/20 (25%). Threemice of the test group developed
squamous–cell carcinomas of the skin (of which 2 in metastasis), 1 had a
leiomyosarcoma of the uterus and 2 treated had lung adenomas. Within the
control group 2 mice had lung adenomas as well.
of the effects reported allowed a derivation of the NOEL or NOAEL. They
only show evidence of the weak carcinogenic potential of benzyl
chloride. The GLP status of the study is unknown, but it is sufficiently
described although further investigation on the clinical signs would be
preferable. Moreover, due to the small size of the group, only
statistical analysis was performed for experiment III. Nevertheless,
these experiments are based on generally well accepted scientific
principles. Therefore, this study should be considered reliable with
restrictions, a Klimisch 2e study.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again